PI3K signalling / / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold.
The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the r...
Saved in:
: | |
---|---|
TeilnehmendeR: | |
Place / Publishing House: | [Lausanne, Switzerland] : : Frontiers Media SA,, 2015. |
Year of Publication: | 2015 |
Language: | English |
Series: | Frontiers Research Topics,
|
Physical Description: | 1 online resource (139 pages). |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993547653404498 |
---|---|
ctrlnum |
(CKB)3710000000526106 (WaSeSS)IndRDA00057317 (oapen)https://directory.doabooks.org/handle/20.500.12854/56255 (EXLCZ)993710000000526106 |
collection |
bib_alma |
record_format |
marc |
spelling |
Martin Turner auth PI3K signalling / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold. Frontiers Media SA 2015 [Lausanne, Switzerland] : Frontiers Media SA, 2015. 1 online resource (139 pages). text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics, 1664-8714 Includes bibliographical references. Description based on: online resource; title from pdf title page (frontiers, viewed Jun. 8, 2016). The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo knockout mice. Together, these experiments have revealed how PI3Ks control B cell and T cell development, T helper cell differentiation, regulatory T cell development and function, B cell and T cell trafficking, immunoglobulin class switching and much, much more. The PI3Kd inhibitor idelalisib has recently been approved for the treatment of B cell lymphoma. Clinical trials of other PI3K inhibitors in autoimmune and inflammatory diseases are also in progress. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology. English Immunologic diseases. B cell PI3K/AKT/mTOR Signal Transduction T cell PI3K pathway inhibitors 2-88919-419-1 Okkenhaug, Klaus, editor. Turner, Martin, editor. Gold, Michael R., editor. |
language |
English |
format |
eBook |
author |
Martin Turner |
spellingShingle |
Martin Turner PI3K signalling / Frontiers Research Topics, |
author_facet |
Martin Turner Okkenhaug, Klaus, Turner, Martin, Gold, Michael R., |
author_variant |
m t mt |
author2 |
Okkenhaug, Klaus, Turner, Martin, Gold, Michael R., |
author2_variant |
k o ko m t mt m r g mr mrg |
author2_role |
TeilnehmendeR TeilnehmendeR TeilnehmendeR |
author_sort |
Martin Turner |
title |
PI3K signalling / |
title_full |
PI3K signalling / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold. |
title_fullStr |
PI3K signalling / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold. |
title_full_unstemmed |
PI3K signalling / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold. |
title_auth |
PI3K signalling / |
title_new |
PI3K signalling / |
title_sort |
pi3k signalling / |
series |
Frontiers Research Topics, |
series2 |
Frontiers Research Topics, |
publisher |
Frontiers Media SA Frontiers Media SA, |
publishDate |
2015 |
physical |
1 online resource (139 pages). |
isbn |
2-88919-419-1 |
issn |
1664-8714 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC582 |
callnumber-sort |
RC 3582 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT martinturner pi3ksignalling AT okkenhaugklaus pi3ksignalling AT turnermartin pi3ksignalling AT goldmichaelr pi3ksignalling |
status_str |
n |
ids_txt_mv |
(CKB)3710000000526106 (WaSeSS)IndRDA00057317 (oapen)https://directory.doabooks.org/handle/20.500.12854/56255 (EXLCZ)993710000000526106 |
carrierType_str_mv |
cr |
is_hierarchy_title |
PI3K signalling / |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796651906639069184 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01282nam a2200325 i 4500</leader><controlfield tag="001">993547653404498</controlfield><controlfield tag="005">20160608103058.0</controlfield><controlfield tag="006">m o u </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">160608s2015 sz |||||o|||||||||||eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000526106</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(WaSeSS)IndRDA00057317</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/56255</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000526106</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">WaSeSS</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">WaSeSS</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC582</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Martin Turner</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">PI3K signalling /</subfield><subfield code="c">topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Lausanne, Switzerland] :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">2015.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (139 pages).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Frontiers Research Topics,</subfield><subfield code="x">1664-8714</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from pdf title page (frontiers, viewed Jun. 8, 2016).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo knockout mice. Together, these experiments have revealed how PI3Ks control B cell and T cell development, T helper cell differentiation, regulatory T cell development and function, B cell and T cell trafficking, immunoglobulin class switching and much, much more. The PI3Kd inhibitor idelalisib has recently been approved for the treatment of B cell lymphoma. Clinical trials of other PI3K inhibitors in autoimmune and inflammatory diseases are also in progress. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Immunologic diseases.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">B cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K/AKT/mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Signal Transduction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K pathway inhibitors</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-419-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okkenhaug, Klaus,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turner, Martin,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gold, Michael R.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-02-22 20:29:15 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2015-12-12 16:57:58 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338608580004498&Force_direct=true</subfield><subfield code="Z">5338608580004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338608580004498</subfield></datafield></record></collection> |